Emcure Pharmaceuticals Limited

Council of Scientific and Industrial Research

Other

Dabur Research Foundation

Emcure Pharmaceutical Limited

Mukund Keshav Gurjar

Samit Satish Mehta

Ramesh Anna Joshi

Narendra Kumar Tripathy

Golakchandra Sudarshan Maikap

Deepak Pragjibhai Gondaliya

Shashikant Gangaram Joshi

Hiren Pravinbhai Patel

Rohini Ramesh Joshi

Muthukrishnan Murugan

Sanjay Pandurang Borikar

Swapnil Panditrao Sonawane

Rajendra Dagesing Mahale

Arpan Suresh Chudasama

Gulabrao Dagadu Patil

Pankaj Shalikrao

Sachin Arvind Badhe

Neha Manubhai Patel

Tushar Pandurang Khaladkar

Prabhakaran Balasubramanian

Prasad Pandurang Panchabhai

Shivnath Bhaupatil Shinde

Pravin Prabhakar Ahirrao

Ashok Tukaram Chaudhari

Dinesh Ramesh Garud

Sanjay Shankar Pawar

Haresh Ishwarbhai Patel

Vijay Keshav Kalhapure

Jhillu Singh Yadav

Rama Mukherjee

Anand C Burman

Manu Jaggi

Suresh Mahadev Kadam

Uttam Ramrao Kalkote

Gautam R Desiraju

Asmita Ashutosh Prabhune

Srivari Chandrasekhar

Satish Ramanlal Mehta

Shreerang V Joshi

Kamal K Kapoor

Sanjay Janardhan Naik

Vishnu Hari Deshpande

Radhika Dilip Wakharkar

K V V M Sairam

Manoj Kumar Thottasseri

Dinesh Rämesh Garud

Sandip Tanaji Salunkhe

Nilesh B Karade

Sachin Aravind Badhe

Baburao Manikroa Bhawal

Aasiya Aslam Burhan

Sougata Pramanick

Kaliaperumal Neelakandan

Neelakandan Kaliaperumal

Raghuramireddy Baireddy

Nandala Srinivas

Srinivas Nandala

Chinmoy Mriganka Pramanik

Sandip B Buchude

Sandeep Anilrao Kotharkar

Jitendra Mohansingh Baweja

Mangesh Gorakhanath Kamble

Pradip Nana Patil

Balaji R Mugale

Pankaj S Patil

Devising Pardeshi

Abdulrakheeb Abdulsubhan Deshmukh

Sanjay Shankar Deshmukh

Satish Ramanial Mehta

Kiran Avinash Bapat

Mangesh Kamble

Vemavarapu P K V Rao

Satyajeet Binay Biswas

Lakindrasing Girase

Jagannath Tulsiram Jagtap

Ashwini Nangia

Hanumant Bapu Rao Borate

Anuo T Singh

Sanjay Sarkhel

Harseh Ishwarbhai Patel

Samit Mehta

Pankaj Shalikrao Patil

Balaji Ram Mugale

Sandip Bajaba Buchude

Balaji Vasant Chaugule

Ganesh Kaluram Karhade

Kaliyaperumal Neelakandan

Ajit Sahebrao Borhade

Jayendra Dattatraya Patole

Pankaj Shallkrao Patil

Devising Rameshsing Pardeshi

The present invention relates to a composition comprising nitrosourea and pharmaceutically acceptable excipients. In particular, the present invention relates to novel drug delivery systems of carmustine such as nano-suspension and micro-emulsion and its use for the treatment of cancer by intravenous administration. Also provided are methods for preparation of such novel drug delivery systems.

Carmustine formulation

The present invention relates to a ready-to-use solution of carmustine that does not require dissolution or dilution of the carmustine prior to addition to saline and dextrose parenteral solutions. In particular, the invention relates to a stable liquid pharmaceutical composition containing carmustine in the form of ready-to-use solution and method for preparing the same.

Stable ready-to-use carmustine pharmaceutical composition

The present invention provides a process for preparation of isoproterenol hydrochloride (1a) comprising catalytic hydrogenation of 3',4&#x2032;-dihydroxy-2-(isopropylamino)-acetophenone hydrochloride (5a) in presence of an ion exchange resin, to provide isoproterenol hydrochloride (1a).

Process for preparation of isoproterenol hydrochloride

The present invention relates to a pharmaceutical lipid composition comprising nitrosoureas and process for its preparation. In particular, the compositions of present invention are useful in the treatment of brain cancers having improved physicochemical and pharmacokinetic characteristics.

Lipid formulations of carmustine

The invention relates to improved method of synthesis for Treprostinil comprising condensation reaction of the carbonyl compound having allyl, alkyl, crotyl or MEM-protected phenolic hydroxyl group, compound (4) with a hydroxyl-protected alkynol (5) to give the condensation product, compound (6). Subjecting compound (6) to oxidation, reduction, hydroxyl protection and carbonylation, cyclization reactions gave the tricyclic derivative (10). Further reactions comprising reduction, hydrogenation and deprotection of the phenolic and side-chain hydroxyl groups, wherein the sequence and choice of reagents was governed by protecting groups, gave the triol intermediate, compound (14). Cyanoalkylation at phenolic hydroxyl functionality and further hydrolysis yielded the prostacyclin compound, Treprostinil (1) and its pharmaceutically acceptable salts, having desired purity.

Process for preparation of prostacyclin derivatives

The present invention provides a process for preparation of trientine dihydrochloride (1) comprising reaction of protected triethylene tetramine with hydrochloric acid in an aqueous system to yield the dihydrochloride salt wherein the formation of inorganic impurities and undesired salts is controlled significantly.

Process for preparation of trientine dihydrochloride

The present invention relates to a stable liquid formulation of cabazitaxel. The formulation comprises cabazitaxel and at least one solubilizer. Typically, formulations are in the form of ready-to-use solutions or concentrates.

Liquid formulation of cabazitaxel

The present invention provides a process for preparation of {(2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethyl)phenyl-3,7-dimethyl-nona-2,4,6,8}tetraenoate, an acitretin intermediate of formula (VI) with trans isomer &#x2265;97%, comprising of reacting 3-formyl-crotonic acid butyl ester of formula (V), substantially free of impurities, with 5-(4-methoxy-2,3,6-trimethylphenyl)-3-methyl-penta-2,4-diene-1-triphenyl phosphonium bromide of formula (IV) and isolating resultant compound of formula (VI), treating the filtrate with iodine for isomerization of the undesired cis intermediate and finally obtaining acitretin (I), with desired trans isomer &#x2265;97%.

Process for preparation of acitrecin

A process for preparation of diethyl 2-aetamido-2-(4-octyl phenyl)ethyl malonate (III), a key intermediate of fingolimod hydrochloride comprising reaction of 2-(4-octylphenyl)ethyl iodide (IV) with diethyl acetamido malonate in presence of a base and an iodinating agent and in an organic solvent. The compound of formula (III) thus obtained provided fingolimod hydrochloride (Ia) having associated impurities below the regulatory limits.

Fingolimod hydrochloride process

The present invention relates to the preparation of stable pyridone disulphide derivatives having general formula (I) and its stereoisomers, which are useful in the treatment of gastrointestinal disorders. Pyridone disulphide derivatives (I) wherein, R, Rand Rare independently alkyl, alkoxy, halogen, halogenated alkoxy, halogenated alkyl, hydrogen and could be the same or different and X is CH or N. Ris methyl, methoxy, fluorine, trifluoromethyl, difluoromethoxy and hydrogen, Ris methyl, methoxy and hydrogen, and Ris methyl and hydrogen.

Pyridone derivatives as acid secretion inhibitors and process for preparation thereof

Controlled release oral dosage formulations containing calcium channel blocker and processes for preparation thereof, are provided for once a day treatment. The active agent is preferably a dihydropyridine calcium channel blocker, such as nisoldipine. In one embodiment, the formulation provides controlled release of micronized nisoldipine with one or more pH independent release controlling polymers. The controlled release matrix formulation is advantageous and can be prepared by a simple, economically viable process as compared to complex core-coat prior-art versions.

Controlled release formulations of nisoldipine

The present invention relates to a novel synthetic route for the preparation of raltegravir and pharmaceutically acceptable salts, starting from 2-amino-2-methylpropanenitrile and oxadiazole carbonyl chloride, through the formation of a pyrimidinone intermediate of formula (V).

Synthesis of Raltegravir

Synthesis of raltegravir

The present invention provides a convenient and industrially viable process for preparation of Zolmitriptan (I) having desired purity. The invention specifically relates to a method for isolating (S)-4-(4-hydrazinobenzyl)-1,3-oxazolidin-2-one hydrochloride (IIIa) of desired purity by separating the undesired inorganic side products such as stannous hydroxide by manipulation of pH at different stages and finally treating with N,N-dimethylamino butyraldehyde diethyl acetal in an acidic medium to provide Zolmitriptan (I) conforming to regulatory specifications.

Process for preparation of zolmitriptan

Growing community of inventors

Pune, India

Mukund Keshav Gurjar